Stopping the beating heart of cancer: KRAS reviewed.

Abstract excerpt

It has taken four decades of research to see the first major breakthrough for KRAS-driven cancers. In particular, the last decade has seen a paradigm shift with the discovery of druggable pockets on KRAS and clinical efficacy with covalent KRASG12C inhibitors, culminating in the first approval of sotorasib monotherapy as second-line treatment in KRASG12C-driven non-small-cell lung cancer. Nevertheless, 85% of all...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Mutation
• Share to Lung Neoplasms
• Share to Carcinoma, Non-Small-Cell Lung